Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piboserod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 17/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.77 |
| ▸ | HRH2 | P25021 | 1/20 | 0.77 |
| ▸ | HTR1D | P28221 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | HRH1 | P35367 | 1/20 | 0.77 |
| ▸ | HTR2B | P41595 | 1/20 | 0.77 |
| ▸ | HTR3A | P46098 | 1/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piboserod SCHEMBL467339 | 0.99 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| Piboserod SCHEMBL30234609 | 0.99 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7333331 | 0.90 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8286732 | 0.89 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7365338 | 0.89 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL6909544 | 0.88 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8287824 | 0.88 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8423110 | 0.88 | HTR4 (0.79) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8287825 | 0.87 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8421844 | 0.87 | HTR4 (0.79) | HTR4CHRM2ADRA2BHRH2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503764-B1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2010-01-06 | — | — | EP | claimed |
| WO-2021116487-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF NIEMANN-PICK C DISEASE | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-06-17 | — | — | WO | disclosed |
| US-10471140-B2 | Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition | NOTTO DENKO CORPORATION (JP) | 2019-11-12 | — | — | US | disclosed |
| US-20190298825-A1 | COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION | NITTO DENKO CORPORATION (JP) | 2019-10-03 | — | — | US | disclosed |
| US-10369219-B2 | Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition | NITTO DENKO CORPORATION (JP) | 2019-08-06 | — | — | US | disclosed |
| US-10286067-B2 | — | — | 2019-05-14 | — | — | US | disclosed |
| US-20170216429-A1 | COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION | NITTO DENKO CORPORATION (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3178491-A1 | COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION | Nitto Denko Corporation (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9533056-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2017-01-03 | — | — | US | disclosed |
| EP-2525830-B1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2016-05-11 | — | — | EP | disclosed |
| EP-1867333-A1 | Pharmaceutical composition comprising condensed indole compound | SMITHKLINE BEECHAM PLC (GB) | 2007-12-19 | — | — | EP | disclosed |
| EP-1313481-B1 | PHARMACEUTICAL COMPOSITION COMPRISING CONDENSED INDOLE COMPOUND | SMITHKLINE BEECHAM PLC (GB) | 2007-09-26 | — | — | EP | disclosed |
| EP-1476136-B1 | PHARMACEUTICAL COMPOSITION COMPRISING N-((1-N-BUTYL-4-PIPERIDINYL)MENTHYL)-3,4-DIHYDRO-2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE OR SALT AND PROCESS FOR PREPARING THEREOF COMPRISING DRY GRANULATION | GLAXO GROUP LTD (GB) | 2006-06-14 | — | — | EP | disclosed |
| US-20060057218-A1 | N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias | SMITHKLINE BEECHAM P.L.C. | 2006-03-16 | — | — | US | disclosed |
| US-20050148582-A1 | Novel composition | SMITHKLINE BEECHAM P.L.C. | 2005-07-07 | — | — | US | disclosed |
| US-20050075335-A1 | Pharmaceutical composition comprising n((1-n-butyl-4-piperidinyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| EP-1476136-A1 | PHARMACEUTICAL COMPOSITION COMPRISING N-((1-N-BUTYL-4-PIPERIDINYL)MENTHYL)-3,4-DIHYDRO-2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE OR SALT AND PROCESS THEREFOR COMPRISING DRY GRANULATION | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068193-A1 | PHARMACEUTICAL COMPOSITION COMPRISING N- ((1-N-BUTYL-4-PIPERIDINYL) METHYL)-3, 4-DIHYDRO-2H- (1, 3) OXAZINO (3, 2-A) INDOLE-10-CARBOXAMIDE OR SALT AND PROCESS THEREFOR COMPRISING DRY GRANULATION | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-0922048-B1 | PROCESS FOR THE PREPARATION OF N- (1-n-BUTYL-4-PIPERIDINYL)METHYL] -3,4-DIHYDRO -2H-[1,3] OXAZINO[3,2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND INTERMEDIATES IN THE PROCESS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-15 | — | — | EP | disclosed |
| US-6100397-A | Process for the preparation of N-[(1-n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process | SMITHKLINE BEECHAM PLC (GB) | 2000-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060057218-A1 | N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias | IDO1, CACNA1E, KCNN4 | HTR4 59/4885CHRM2 595/4885ADRA2B 831/4885 |
| US-20050148582-A1 | Novel composition | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDO1, AANAT | HTR4 41/4885CHRM2 315/4885ADRA2B 203/4885 |
| US-20050075335-A1 | Pharmaceutical composition comprising n((1-n-butyl-4-piperidinyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation | IDO1, HINT1, HTR1D | HTR4 11/4885CHRM2 391/4885ADRA2B 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.